ImmunityBio, Inc.
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
Inclusion Criteria: * Age ≥ 18 and \< 70 years. * History of at least one SARS-CoV-2 infection, defined as report of a positive nucleic acid amplification test (NAAT) and/or a positive SARS-CoV-2 antigen rapid diagnostic test (RDT). Those with only suspected but unconfirmed infections are not eligible for this study. * Clinical evidence of Long COVID, as confirmed by the Investigator's assessment. 1. At least 2 symptoms or at least 1 severe symptom as assessed by the study team (see list) that are new or worsened since the time of a SARS-CoV-2 infection, not known to be attributable to ano…
600ug of NAI administered subcutaneously
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.